fashion -WSS

fashion

author：knowledge 2025-09-29 01:07:14 - browse：41748

Adam's take main illustration — Molly Ferguson/STAT

The Food and Drug Administration should halt Cassava Sciences’ ongoing clinical trials in Alzheimer’s disease. That, and other thoughts on the fallout from the City University of New York investigation that raised serious doubts about the science underpinning the company’s experimental drug simufilam.

Patient safety is paramount to the FDA, so stopping Cassava’s two Phase 3 studies is the ethically correct thing to do.The FDA has the power to place clinical holds on experimental drugs when there’s evidence of an unacceptable safety risk to study participants. Simufilam doesn’t appear to be toxic. It’s not causing dangerous side effects. But study participants can also be harmed when they volunteer for a clinical trial based on false or misleading information about a drug’s potential efficacy.

The CUNY committee charged with investigating Cassava’s principal scientific collaborator, the neuroscientist Hoau-Yan Wang, could not definitively prove that Wang faked simufilam data, but that’s only because he refused to turn over original data and primary research records that the committee had requested to examine. Wang also claimed that boxes of research records relevant to the investigation were thrown away. The investigative report was first made public last week in the journal Science.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Congress considering partial increase for doctor pay in Medicare

WSS

Too many hospitalized Covid

Where does female orgasm come from? Scientists think they know

Readout Newsletter: Amylyx, Aurinia, and IQVIA

My chronic pain journey would have been easier knowing 5 things % STAT

Congress considering partial increase for doctor pay in Medicare

Readout Newsletter: Amylyx, Aurinia, and IQVIA

hotspot

fashion

explore

Walensky prepares to leave CDC — and Congress — behind

Doctors have an ethical obligation to be advocates

In Memoriam: Notable people who died in 2023

Statins reduce cardiovascular risk in people living with HIV

Virginia high school admissions case could be legal follow

Weekend shootings leave at least 6 dead, 20 others wounded in Chicago

Wildfire smoke exposes gaps in outdoor worker protections

Juul documents reveal insider tactics on political lobbying

Hepatitis C has a cure — but many Americans still lack access to it

Resistance to opioid

leisure time

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Clinic falsely told dozens they had Alzheimer's, suits say

Report cites 'urgent' need to recruit more diverse clinical trial participants

Transgender women dream of pregnancy via uterus transplants

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

hotspot

entertainment

leisure time

knowledge